Loading…

Sustained Activation of Glial Cell Epidermal Growth Factor Receptor by Bis(thiosemicarbazonato) Metal Complexes Is Associated with Inhibition of Protein Tyrosine Phosphatase Activity

Bis(thiosemicarbazonato) metal complexes (MII(btsc)) have demonstrated potential neuroprotective activity in cell and animal models of Alzheimer’s disease (AD). Metal complexes can activate the epidermal growth factor receptor (EGFR), leading to inhibition of amyloid peptide accumulation in neuronal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2009-11, Vol.52 (21), p.6606-6620
Main Authors: Price, Katherine Ann, Caragounis, Aphrodite, Paterson, Brett M, Filiz, Gulay, Volitakis, Irene, Masters, Colin L, Barnham, Kevin J, Donnelly, Paul S, Crouch, Peter J, White, Anthony R
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bis(thiosemicarbazonato) metal complexes (MII(btsc)) have demonstrated potential neuroprotective activity in cell and animal models of Alzheimer’s disease (AD). Metal complexes can activate the epidermal growth factor receptor (EGFR), leading to inhibition of amyloid peptide accumulation in neuronal cells. As glial cells also have an important role in modulating neuronal health and survival in AD, we examined the effect of MII(btsc) on activity of EGFR in an astroglial cell line. Our findings reveal potent activation of glial EGFR by glyoxalbis(N(4)-methylthiosemicarbazonato)CuII] (CuII(gtsm)). Activation of EGFR by CuII(gtsm) involved phosphorylation of multiple tyrosine residues and was mediated by a cognate ligand-independent process involving MII(btsc) inhibition of protein tyrosine phosphatase (PTP) activity. EGFR activation resulted in release of growth factors and cytokines with potential modulatory effects on neuronal function. These studies provide an important insight into the mechanism of action of a neuroprotective MII(btsc) and provide a basis for future studies into this novel approach to AD therapy.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm9007938